mBraze – Digital support for breast cancer

The digital intervention mBraze is designed for women receiving hormone therapy after breast cancer (Tamoxifen).

The app aims to reduce late effects or side effects of the treatment and improve quality of life. The goal is to help more women continue their treatment and lower their risk of cancer returning. In the long run, mBraze hopes to reduce healthcare use, rehabilitation needs, and sick leave days.

mBraze was created with help from healthcare staff, patients, clinical researchers, pharmaceutical companies, and medical technology companies to support patients and clinics.

Target Group

Patients with hormone receptor-positive breast cancer receiving adjuvant endocrine treatment.

Purpose

To reduce late effects or side effects of treatment, improve quality of life, increase the number of women who complete their treatment, and help reduce healthcare use, rehabilitation needs, and sick leave days.

Ongoing Validation

mBraze was tested in a pilot study with 15 patients in 2018 (scientific publication). It was further developed in 2021-2022 after additional needs analysis with contact nurses and patients.

The PACED research study (RCT) will involve 300 patients with a 12-month intervention from 2022 to 2024 at Region Stockholm’s breast centers: Capio St Görans Hospital.

Görans Hospital, Karolinska University Hospital, and Södersjukhuset. The study is sponsored by the Breast Cancer Association, Novartis Sweden, AstraZeneca, and Region Stockholm’s Innovation Fund.

Regulatory

mBraze is available on a CE-marked (MDR) medical technology platform.

Read more about the development and application of digital therapies here.

Läs mer om utveckling och tillämpning av digitala terapier här.

PACED mBraze – patient-centred support in everyday life